Pharmaceutical Market Trends, 2010 - 2014


October 1, 2010
142 Pages - SKU: URC2852481
License type:
Table of Contents Search inside this report Related Reports
Summary
Introduction
Key global markets
Key therapeutic markets
Key products
Key companies
Key trends and opportunities
Chapter 1. Introduction
Global pharmaceutical market
Report overview
Methodology
Sources
Structure
Chapter 2. Key global markets
Key pharmaceutical markets
US pharmaceutical market
US purchasing channels
US market leaders
European pharmaceutical market
European purchasing channels
Japanese pharmaceutical market
Chapter 3. Key therapeutic markets
Key therapy areas
Key product classes
CNS therapy area
CNS blockbusters
Cardiovascular therapy area
Cardiovascular blockbusters
Alimentary/metabolism therapy area
Alimentary/metabolism blockbusters
Antineoplastic/immunomodulatory therapy area
Antineoplastic/immunomodulatory blockbusters
Anti-infectives therapy area
Anti-infectives blockbusters
Respiratory therapy area
Respiratory blockbusters
Chapter 4. Key products
Leading products
Lipitor (atorvastatin)
Plavix/Iscover (clopidogrel)
Seretide/Advair (fluticasone/salmeterol)
Remicade (infliximab)
Enbrel (etanercept)
Diovan/Co-Diovan (valsartan/hydrochlorothiazide)
Avastin (bevacizumab)
Rituxan (rituximab)
Humira (adalimumab)
Seroquel (quetiapine)
Blockbuster trends
Blockbusters by drug type
Blockbusters by therapy area
Blockbusters by company
Chapter 5. Key companies
Major pharmaceutical companies
Major company financials
Major company locations
Top 10 pharmaceutical companies
Top 10 company financials
Top 10 company value drivers
Leading pharmaceutical companies
Pfizer
Sanofi-Aventis
Novartis
GlaxoSmithKline
Roche
AstraZeneca
Merck & Co
Johnson and Johnson
Eli Lilly
Bristol-Myers Squibb
Chapter 6. Key trends and opportunities
Global market forecasts
The US market
The European market
The Japanese market
Other markets
Key therapy area forecasts
CNS market
Cardiovascular market
Alimentary/metabolism market
Antineoplastic/immunomodulatory market
Anti-infectives market
Respiratory market
Key product forecasts
Lipitor (atorvastatin)
Plavix/Iscover (clopidogrel)
Seretide/Advair (fluticasone/salmeterol)
Remicade (infliximab)
Enbrel (etanercept)
Diovan/Co-Diovan (valsartan/hydrochlorothiazide)
Avastin (bevacizumab)
Rituxan/MabThera (rituximab)
Humira (adalimumab)
Seroquel (quetiapine)
Key company forecasts
Pfizer
Sanofi-Aventis
Novartis
GlaxoSmithKline
Roche
AstraZeneca
Merck & Co
Johnson and Johnson
Eli Lilly
Bristol-Myers Squibb
Appendix
Proprietary data sources
Product Trends Database
Company Trends Database
Top 125 pharmaceutical products
Top 59 pharmaceutical companies
Figures
Figure 1: Global pharmaceutical market, 1999-2009
Figure 2: Report structure
Figure 3: Global pharmaceutical market share by region, 2009
Figure 4: Global pharmaceutical market by region, 2005-2009
Figure 5: US pharmaceutical market, 2005-2009
Figure 6: US pharmaceutical market share by purchasing channel, 2009
Figure 7: US pharmaceutical market by purchasing channel, 2005-2009
Figure 8: Top 10 products by US pharmaceutical sales, 2009
Figure 9: Top 10 companies by US pharmaceutical sales, 2009
Figure 10: Top 10 companies by share of US pharmaceutical sales, 2009
Figure 11: European pharmaceutical market, 2003-2009
Figure 12: European pharmaceutical market share by country, 2009
Figure 13: European pharmaceutical market by purchasing channel, 2009
Figure 14: Japanese pharmaceutical market, 2003-2009
Figure 15: Global pharmaceutical market by therapy area, 2009
Figure 16: Top 10 product classes by global pharmaceutical sales, 2009
Figure 17: CNS pharmaceutical market, 2005-2009
Figure 18: Cardiovascular pharmaceutical market, 2005-2009
Figure 19: Alimentary/metabolism pharmaceutical market, 2005-2009
Figure 20: Antineoplastic/immunomodulatory pharmaceutical market, 2008-2009
Figure 21: Anti-infectives pharmaceutical market, 2005-2009
Figure 22: Respiratory pharmaceutical market, 2005-2009
Figure 23: Blockbuster drug sales share by drug type, 2009
Figure 24: Blockbuster drug sales share by lifecycle stage, 2009
Figure 25: Blockbuster drug sales share by therapy area, 2009
Figure 26: Blockbuster drug sales share by company, 2009
Figure 27: Major companies pharmaceutical sales, 2007-2009
Figure 28: Major companies revenue share allocation, 2009
Figure 29: Major companies revenue allocation, 2007-2009
Figure 30: Major companies pharmaceutical sales by location, 2009
Figure 31: Top 10 pharma companies pharmaceutical sales, 2007-2009
Figure 32: Top 10 pharma companies by global pharmaceutical sales, 2009
Figure 33: Top 10 biotechnology companies by global revenues, 2009
Figure 34: Top 10 pharma companies revenue share allocation, 2009
Figure 35: Top 10 pharma companies revenue allocation, 2007-2009
Figure 36: Key value drivers for top 10 pharma companies (income), 2009
Figure 37: Key value drivers for top 10 pharma companies (sales), 2009
Figure 38: Key value drivers for top 10 pharma companies (sales/R&D), 2009
Figure 39: Pfizer therapy area sales, 2007-2009
Figure 40: Sanofi-Aventis blockbuster therapy area sales, 2007-2009
Figure 41: Novartis therapy area sales, 2007-2009
Figure 42: GlaxoSmithKline therapy area sales, 2007-2009
Figure 43: Roche therapy area sales, 2007-2009
Figure 44: AstraZeneca therapy area sales, 2007-2009
Figure 45: Merck & Co blockbuster therapy area sales, 2007-2009
Figure 46: Johnson and Johnson blockbuster therapy area sales, 2007-2009
Figure 47: Eli Lilly therapy area sales, 2007-2009
Figure 48: Bristol-Myers Squibb blockbuster therapy area sales, 2007-2009
Figure 49: Global pharmaceutical market forecast, 2005-2014
Figure 50: Global pharmaceutical market forecast by regions, 2005-2014
Figure 51: Top 10 pharmaceutical drugs by forecast sales, 2014
Figure 52: Lipitor (atorvastatin) forecast sales, 2007-2014
Figure 53: Plavix/Iscover (clopidogrel) forecast sales, 2007-2014
Figure 54: Seretide/Advair (fluticasone/salmeterol) forecast sales, 2007-2014
Figure 55: Remicade (infliximab) forecast sales, 2007-2014
Figure 56: Enbrel (etanercept) forecast sales, 2007-2014
Figure 57: Diovan/Co-Diovan (valsartan/hydrochlorothiazide) forecast sales, 2007-2014
Figure 58: Avastin (bevacizumab) forecast sales, 2007-2014
Figure 59: Rituxan/MabThera (rituximab) forecast sales, 2007-2014
Figure 60: Humira (adalimumab) forecast sales, 2007-2014
Figure 61: Seroquel (quetiapine) forecast sales, 2007-2014
Tables
Table 1: Global pharmaceutical market trends by region, 2007-2009
Table 2: US pharmaceutical market trends by purchasing channel, 2007-2009
Table 3: Top 10 products trends by US pharmaceutical sales, 2007-2009
Table 4: Global pharmaceutical market trends by therapy area, 2007-2009
Table 5: Top 10 product classes trends by global pharmaceutical sales, 2007-2009
Table 6: CNS blockbuster drug sales, 2007-2009
Table 7: Cardiovascular blockbuster drug sales, 2005-2009
Table 8: Alimentary/metabolism blockbuster drug sales, 2007-2009
Table 9: Antineoplastic/immunomodulatory blockbuster drug sales, 2007-2009
Table 10: Anti-infectives blockbuster drug sales, 2007-2009
Table 11: Respiratory blockbuster drug sales, 2007-2009
Table 12: Top 20 products by global pharmaceutical sales, 2007-2009
Table 13: Lipitor (atorvastatin) profile, 2009
Table 14: Plavix/Iscover (clopidogrel) profile, 2009
Table 15: Seretide/Advair (fluticasone/salmeterol) profile, 2009
Table 16: Remicade (infliximab) profile, 2009
Table 17: Enbrel (etanercept) profile, 2009
Table 18: Diovan/Co-Diovan (valsartan/hydrochlorothiazide) profile, 2009
Table 19: Avastin (bevacizumab) profile, 2009
Table 20: Rituxan (rituximab) profile, 2009
Table 21: Humira (adalimumab) profile, 2009
Table 22: Seroquel (quetiapine) profile, 2009
Table 23: Top 10 blockbuster products by global pharmaceutical sales growth, 2007-2009
Table 24: Top 10 blockbuster products by declining global pharmaceutical sales, 2007-2009
Table 25: New blockbuster products, 2007-2009
Table 26: Major companies revenue allocation trends, 2007-2009
Table 27: Top 10 pharma companies by global pharmaceutical sales, 2007-2009
Table 28: Top 10 biotechnology companies by global revenues, 2007-2009
Table 29: Top 10 pharma companies revenue allocation trends, 2007-2009
Table 30: Pfizer profile, 2009
Table 31: Pfizer blockbuster sales, 2007-2009
Table 32: Wyeth blockbuster sales, 2007-2009
Table 33: Sanofi-Aventis profile, 2009
Table 34: Sanofi-Aventis blockbuster sales, 2007-2009
Table 35: Novartis profile, 2009
Table 36: Novartis blockbuster sales, 2007-2009
Table 37: GlaxoSmithKline profile, 2009
Table 38: GlaxoSmithKline blockbuster sales, 2007-2009
Table 39: Roche profile, 2009
Table 40: Roche blockbuster sales, 2007-2009
Table 41: Genentech blockbuster sales, 2007-2009
Table 42: AstraZeneca profile, 2009
Table 43: AstraZeneca blockbuster sales, 2007-2009
Table 44: Merck & Co profile, 2009
Table 45: Merck & Co blockbuster sales, 2007-2009
Table 46: Schering-Plough blockbuster sales, 2007-2009
Table 47: Johnson and Johnson profile, 2009
Table 48: Johnson and Johnson blockbuster sales, 2007-2009
Table 49: Eli Lilly profile, 2009
Table 50: Eli Lilly blockbuster sales, 2007-2009
Table 51: Bristol-Myers Squibb profile, 2009
Table 52: Bristol-Myers Squibb blockbuster sales, 2007-2009
Table 53: Global pharmaceutical market forecast by regions, 2005-2014
Table 54: Global pharmaceutical market forecast by therapy area, 2009-2014
Table 55: Top 10 pharmaceutical drugs forecast, 2007-2014
Table 56: Top 10 pharmaceutical companies forecast, 2009-2014
Table 57: Top 125 products by global pharmaceutical sales, 2007-2009
Table 58: Top 59 companies by global pharmaceutical sales, 2007-2009
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Prescription Drugs Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!